Cargando…

Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia

The inhibition by imatinib of the cytochrome P450 3A4 isoenzyme may reduce the CYP3A4-mediated metabolic clearance of clinically important coadministered drugs. The main purpose of this study was to evaluate the effect of the coadministration of imatinib on the pharmacokinetics of simvastatin, a pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	O'Brien, S G, Meinhardt, P, Bond, E, Beck, J, Peng, B, Dutreix, C, Mehring, G, Milosavljev, S, Huber, C, Capdeville, R, Fischer, T
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2003
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394453/ https://www.ncbi.nlm.nih.gov/pubmed/14612892 http://dx.doi.org/10.1038/sj.bjc.6601152

Ejemplares similares

Management of Skin Toxicity Related to the Use of Imatinib Mesylate (STI571, Glivec™) for Advanced Stage Gastrointestinal Stromal Tumours
por: Scott, Lucy C., et al.
Publicado: (2005)

Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571)
por: Pinder, Elizabeth M., et al.
Publicado: (2007)

Tuberculous and Non-Tuberculous Granulomatous Lymphadenitis in Patients Receiving Imatinib Mesylate (Glivec) for Metastatic Gastrointestinal Stromal Tumor
por: Agaimy, Abbas, et al.
Publicado: (2013)

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec(®), Gleevec™)
por: Henkes, Martin, et al.
Publicado: (2008)

Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease
por: Re, D, et al.
Publicado: (2002)

Effects of STI571 (gleevec) on pancreatic cancer cell growth
por: Li, Junsheng, et al.
Publicado: (2003)

Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study
por: Gemelli, Maria, et al.
Publicado: (2020)

Imatinib (STI571) Inhibits the Expression of Angiotensin-Converting Enzyme 2 and Cell Entry of the SARS-CoV-2-Derived Pseudotyped Viral Particles
por: Lin, You-Zhe, et al.
Publicado: (2021)

Effectiveness of imatinib mesylate over etoposide in the treatment of sensitive and resistant chronic myeloid leukaemia cells in vitro
por: Husaini, Roslina, et al.
Publicado: (2017)

The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR–ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents
por: Liu, W M, et al.
Publicado: (2002)

Periorbital edema secondary to imatinib mesylate
por: McClelland, Collin M, et al.
Publicado: (2010)

Cutaneous adverse effects of imatinib mesylate
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2015)

Imatinib Mesylate-Induced Hyperpigmentation of the Nose and Palate
por: Song, Hyo Sang, et al.
Publicado: (2014)

Imatinib mesylate resistance and mutations: An Indian experience
por: Srivastava, Shweta, et al.
Publicado: (2013)

Lichenoid drug eruption due to imatinib mesylate
por: Bhatia, Anuradha, et al.
Publicado: (2015)

The teratogenic effects of imatinib mesylate on rat fetuses
por: El Gendy, M.M., et al.
Publicado: (2015)

Exacerbation of Psoriasis after Imatinib Mesylate Treatment
por: Shim, Joon Ho, et al.
Publicado: (2016)

Impact of Fas/Fasl Gene Polymorphisms on Susceptibility Risk and Imatinib Mesylate Treatment Response in Chronic Myeloid Leukaemia Patients
por: Annuar, Aziati Azwari, et al.
Publicado: (2021)

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
por: Din, Omar S, et al.
Publicado: (2008)

The role of c-kit and imatinib mesylate in uveal melanoma
por: Pereira, Patricia Rusa, et al.
Publicado: (2005)

Plantar Keratoderma with Pachyonychia Likely Induced by Imatinib Mesylate
por: Kim, Hyung Ok, et al.
Publicado: (2013)

Ageing is a risk factor in imatinib mesylate cardiotoxicity
por: Maharsy, Wael, et al.
Publicado: (2014)

Molecular Mobility and Stability Studies of Amorphous Imatinib Mesylate
por: Karolewicz, Bożena, et al.
Publicado: (2019)

Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate
por: Pautier, Patricia, et al.
Publicado: (2013)

Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro
por: Zhang, Peilin, et al.
Publicado: (2003)

Changing therapy from Glivec(® )to a "copy" imatinib results in a worsening of chronic myeloid leukemia disease status: two case reports
por: Asfour, Inas A, et al.
Publicado: (2009)

“To patent or not to patent? the case of Novartis’ cancer drug Glivec in India”
por: Gabble, Ravinder, et al.
Publicado: (2014)

Imatinib Mesylate-Induced Erythema Multiforme: Recurrence after Rechallenge with 200 mg/day Imatinib
por: Lee, Min Kyung, et al.
Publicado: (2015)

Phase II trial of imatinib mesylate in patients with metastatic melanoma
por: Kim, K B, et al.
Publicado: (2008)

Metastatic duodenal GIST: role of surgery combined with imatinib mesylate
por: Mohiuddin, Kamran, et al.
Publicado: (2007)

ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor
por: Rink, Lori, et al.
Publicado: (2013)

Generalized Lichenoid Drug Eruption Associated with Imatinib Mesylate Therapy
por: Ghosh, Sudip Kumar
Publicado: (2013)

Prediction of Sensitivity to STI571 among Chronic Myeloid Leukemia Patients by Genome‐wide cDNA Microarray Analysis
por: Kaneta, Yasuyuki, et al.
Publicado: (2002)

Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model
por: Li, Minglun, et al.
Publicado: (2009)

Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
por: Dufresne, A, et al.
Publicado: (2010)

Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia
por: Hu, Zheng, et al.
Publicado: (2009)

Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec™)
por: Cho, Ah Young, et al.
Publicado: (2011)

In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells
por: Weigel, Marion T, et al.
Publicado: (2010)

Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours
por: Gauden, Ruth, et al.
Publicado: (2011)

Imatinib Mesylate-Induced Cutaneous Rash Masquerading as Pityriasis Rosea of Gilbert
por: Verma, Prashant, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_btpq6076c1ihv55naca7tinf8r